Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154708 | 0.79 | LMNA (0.65) | MAOBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL29459415 | 0.79 | LMNA (0.65) | MAOBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1136696 | 0.77 | MAPT (0.63) | MAOBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL30304403 | 0.77 | MAPT (0.63) | MAOBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL23625930 | 0.77 | L3MBTL1 (0.40) | MAOBMEN1KMT2AALDH1A1CASP3 | |
| SCHEMBL30952891 | 0.77 | L3MBTL1 (0.40) | MAOBMEN1KMT2AALDH1A1CASP3 | |
| SCHEMBL3561759 | 0.76 | SIRT2 (0.40) | CYP2A6MAOBMEN1KMT2AMAPT | |
| SCHEMBL17849092 | 0.75 | CYP2A6 (0.68) | CYP2A6MEN1KMT2AMAPTKDM4E | |
| SCHEMBL148642 | 0.75 | CYP2A6 (0.68) | CYP2A6MEN1KMT2AMAPTKDM4E | |
| SCHEMBL17849089 | 0.75 | CYP2A6 (0.68) | CYP2A6MEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071598-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-12-06 | — | — | US | disclosed |
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-06-24 | — | — | US | disclosed |
| US-7700596-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-20 | — | — | US | disclosed |
| US-20090036456-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A3, SLC6A2 | CYP2A6 429/4885MAOB 8/4885MEN1 1894/4885 |
| US-20090036456-A1 | 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | CYP2A6 536/4885MAOB 7/4885MEN1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.